Abbott (ABT): analysis in plain words
Is Abbott cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.
Abbott (ABT) is listed on the NYSE and we classify it in healthcare and pharma. Below are its key dated figures, how it makes money, how it compares with its sector, what works for and against Abbott according to those figures, and the questions people ask most about the stock. No buy or sell tips.
Abbott (ABT) key figures as of November 4, 2026
| Figure | Value | What it measures |
|---|---|---|
| Share price | $115.51 | Last price on November 4, 2026 |
| P/E ratio (TTM) | 42.9x | Price over earnings per share |
| Revenue growth | +14.5% | Latest quarter vs the same quarter a year earlier |
| Net margin (TTM) | 9.7% | Profit for every 100 of sales |
| Net debt / EBITDA | 2.3x | Years of operating profit to repay debt |
| Dividend yield | 2.30% | Annual dividend over price |
| Market cap | $199.9 billion | What the stock market values it at |
The Abbott figures come from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026. Any ABT figure that is not available shows as N/A: we do not estimate it.
How Abbott makes money
Abbott reports four segments: Medical Devices, the largest, including FreeStyle Libre glucose sensors and heart devices; Diagnostics, selling lab analyzers and tests; Nutrition, with Similac, PediaSure and Ensure; and Established Pharmaceuticals, branded generic drugs sold in emerging markets. It operates in the U.S. and internationally.
Over the last 12 months, Abbott brought in revenue of $48.2 billion. For every 100 it sells, Abbott keeps 57.1 after the direct cost of what it sells (gross margin) and 11.3 after all operating costs (operating margin). With 122,000 full-time employees, that is about $395,000 of revenue per employee.
Abbott against its sector
To know whether a Abbott figure is high or low you have to put it next to similar companies. This table compares Abbott with the median of the 30 healthcare and pharma companies Fintols covers, with data as of November 4, 2026.
| Figure | Abbott | healthcare and pharma median |
|---|---|---|
| P/E | 42.9x | 31.3x (30) |
| Revenue growth | +14.5% | +8.3% (33) |
| Net margin | 9.7% | 14.9% (33) |
| Dividend yield | 2.30% | 1.52% (33) |
| Net debt / EBITDA | 2.3x | 1.6x (31) |
In short, against the typical healthcare and pharma company, Abbott trades on a higher P/E, grows faster and earns a thinner margin. By size, Abbott ranks number 9 of 28 healthcare and pharma companies quoted in USD on Fintols.
The bull case for Abbott
These are the strengths in the Abbott figures as of November 4, 2026:
- Analysts expect Abbott earnings to rise: its P/E on the next 12 months of estimated earnings is 19.5x, below the current 42.9x.
- Abbott is selling more than a year ago: +14.5% in its latest quarter (the typical healthcare and pharma company grew +8.3%).
The main risk for Abbott
The Abbott figures as of November 4, 2026 show no clear red flag (no heavy debt, no losses, no falling sales). Its main risk is the one built into its business: a key drug losing patent protection or a clinical trial failing, plus government pressure on prices.
Frequently asked questions about Abbott
Is it a good time to buy Abbott stock?
Fintols does not tell you whether to buy or sell Abbott, and nobody knows what the price will do tomorrow. What we can show you is where it stands today. As of November 4, 2026, Abbott stock trades at $115.51, 13% below its 52-week high ($132.03) and 41% above its low ($81.97). Its P/E is 42.9x against a healthcare and pharma median of 31.3x, and 19.5x on the earnings analysts expect over the next 12 months. With Abbott, as with any stock, timing matters less than understanding the business, investing for the long run and not betting everything on a single company.
Does Abbott pay a dividend?
Yes. As of November 4, 2026, Abbott pays $2.52 per share a year, which at today's price is a yield of 2.30%. It uses 79% of its profit to pay it. Its average dividend yield over the last five years is 1.86%. The healthcare and pharma median on Fintols is 1.52%.
Is Abbott stock expensive?
It depends on what you compare it with. On P/E, Abbott trades at 42.9x its last 12 months of earnings: more expensive than the healthcare and pharma median (31.3x). Including its debt, Abbott is valued at 18.2x its EBITDA (EV/EBITDA). A high P/E alone does not make Abbott expensive: it can be justified if earnings grow fast, and a low one can reflect a business in trouble.
Who are Abbott's competitors?
On Fintols we compare Abbott with AbbVie, Amgen and Eli Lilly, which are also in healthcare and pharma. As of November 4, 2026, AbbVie is worth $521.0 billion and trades on a P/E of 50.7; Amgen is worth $258.7 billion and trades on a P/E of 29.7; Eli Lilly is worth $1.26 trillion and trades on a P/E of 46.0. Each has a side-by-side comparison with Abbott below.
Abbott competitors
- AbbVie (ABBV) analysis · Abbott vs AbbVie comparison
- Amgen (AMGN) analysis · Abbott vs Amgen comparison
- Eli Lilly (LLY) analysis · Abbott vs Eli Lilly comparison
To understand Abbott better
- DCF and WACC Explained: A Practical Valuation Guide
- P/E Ratio and EPS Explained: How to Read Them Without Traps
More companies like Abbott: healthcare and pharma stocks, S&P 500 companies and S&P 100 companies. Open the full ABT analysis with its valuation and scenarios. Educational content about Abbott, not investment advice.